Kymera Investor Day Presentation Deck | Slidebook.io

Kymera Investor Day Presentation Deck

December 2021, 105 slides

day a | Kymera

forward looking statements | Kymera

day founder president and | Kymera

editing is the new frontier of medicine genome | Kymera

editing with targeted protein degradation | Kymera

expanding with targeted protein degradation all therapeutic modalities to date only drug up to of is expanding the drugged with targeted protein degradation | Kymera

exponential clinical pipeline growth of degraders targeted protein degradation | Kymera

today speakers | Kymera

today agenda | Kymera

a global company | Kymera

introduction to | Kymera

pipeline of novel protein degraders | Kymera

differentiated approach to as | Kymera

our people culture | Kymera

our first years a foundation for the future | Kymera

day objectives | Kymera

clinical pipeline a | Kymera

agenda degrader study sad mad data degrader update and clinical plans degrader update and clinical plans degraders in immune inflammation and fibrosis phi | Kymera

safety and from sad and mad dose portion of phase trial in healthy volunteers jared chief medical officer | Kymera

targeting degrader advantage clinical validation and human genetics risking | Kymera

development opportunities for degrader in inflammation | Kymera

protein expression in diseases | Kymera

multiple transcripts are and correlate with protein levels in skin lesions a | Kymera

potent and specific degradation with impact on superior to kinase inhibition | Kymera

is superior to small molecule inhibitor across multiple preclinical immune inflammatory in models | Kymera

phase trial design includes and patients | Kymera

sad mad enrollment status and demographics sad mad female male median age years range or black or non or white | Kymera

achieved degradation after single dose | Kymera

stimulation methodology in phase trial | Kymera

broad and deep inhibition of disease relevant | Kymera

demonstrates anti inflammatory effect compared to other clinical agents | Kymera

blinded sad safety summary | Kymera

mad study once daily dosing resulted in high steady state exposures | Kymera

achieved near complete and sustained degradation with multiple daily oral doses days | Kymera

lower daily doses of achieved degradation | Kymera

achieved degradation in monocytes at flow i | Kymera

once daily dosing days resulted in high skin exposures exceeding plasma | Kymera

mad reduced to near in the skin | Kymera

substantial degradation in skin observed in dermis and epidermis red | Kymera

inhibition of disease relevant day a pray | Kymera

blinded mad safety summary mad | Kymera

summary of phase sad mad | Kymera

development in inflammatory diseases patel head of global development immunology and inflammation day | Kymera

| Kymera

approach to | Kymera

rich immunology portfolio extending to other tas | Kymera

is a key initiator of type and type inflammation of mucosal tissues via and family receptors | Kymera

first in class oral protein degrader sar or entered the clinic in initial indications atopic dermatitis and hidradenitis | Kymera

degrader update and clinical plans head of development | Kymera

are potent degraders of and substrates targeting redundant pro survival pathways in fag | Kymera

first precision medicine in mutated cancers us us us | Kymera

is a potent degrader of and substrates with potent activity in cell lines | Kymera

is highly active on intermittent dosing regimens | Kymera

has strong activity in combination in | Kymera

clinical study design and objectives | Kymera

registration strategies | Kymera

degrader has potential to be first precision medicine in to target a genetically defined population profound activity in preclinical models both in single agent and combination clinical strategy in place to enable accelerated approval combinations | Kymera

degrader update and clinical plans head of development | Kymera

has unique tumor cell intrinsic and extrinsic mechanisms pal | Kymera

first in class opportunity to address driven pathology across diverse indications us us us us of go | Kymera

demonstrates highly selective degradation of log | Kymera

full and durable regressions across multiple in preclinical tumor models | Kymera

degrader role in oncology sensitization of tumors to anti a | Kymera

clinical study design and objectives | Kymera

accelerated and full approval strategies across several indications nake | Kymera

degrader first in class opportunity to address driven pathology across diverse indications first degrader against an undrugged target in the clinic profound single agent activity in liquid tumor and promising activity with anti in liquid and solid tumors clinical development strategy includes direct registrational path in pathway activated heme malignancies opportunity for expansion into solid tumors in combination with immune inhibitors | Kymera

degraders in immune inflammation and fibrosis head of development | Kymera

role of in inflammatory processes | Kymera

degraders have applicability in serious inflammatory and fibrotic diseases us us us | Kymera

our degraders robustly reduce disease in models of systemic sclerosis arthritis and inflammation | Kymera

program will continue following a short break stall seas | Kymera

discovery pipeline principles head of biology | Kymera

how we select our targets a validated | Kymera

to deliver per year | Kymera

a first in class degrader in development for solid and liquid tumors head of biology | Kymera

is the that modulates the tumor suppressor | Kymera

degradation not inhibition efficiently restores | Kymera

degrader development candidate is superior to small molecule inhibitors | Kymera

unlike small molecule inhibitors overcome the and feedback loop | Kymera

short term exposure to degrader but not is sufficient to commit cells to undergo | Kymera

single dose of leads to sustained tumor regression | Kymera

dependency seen across a large subset of tumor types large franchise potential in liquid and solid tumors | Kymera

focus on indications where degradation leads to acute response ree | Kymera

is a potent degrader and a best in class stabilizer with potential to treat numerous tumors | Kymera

expanding the drugged platform head of drug discovery | Kymera

targeted protein degradation | Kymera

we want to drug all target classes | Kymera

proprietary platform | Kymera

novel to drug a new generation of targets | Kymera

has engaged a broadly expressed protein in only one cell type using a tissue selective | Kymera

tissue selective degradation drives increase of therapeutic index | Kymera

a comprehensive hit finding toolbox rapidly enables new discovery against all target classes | Kymera

successful examples of fragment and covalent screens | Kymera

can develop degraders with predictable drug like properties rat min dog min monkey min | Kymera

mechanistic modeling allowed to accurately predict human and from preclinical dog data for clinical candidate | Kymera

rationally designing molecular glues to drug historically undrugged targets | Kymera

expanding the with | Kymera

vision founder and | Kymera

what we showed you today | Kymera

pipeline today | Kymera

what we expect in | Kymera

our year vision where will be in | Kymera

what clinical pipeline could look like in a | Kymera

what we hope you will take from today targeted protein degradation is positioned to transform drug development landscape is a medicine focused company with recognized leadership in we employ a novel and differentiated scientific strategy and approach around target selection drug development and platform investments we are committed to innovation execution and to the pursuit of real step change in treatment paradigms there is much we have accomplished since our founding but even more we expect to deliver in and beyond we have a very ambitious but achievable vision for the company | Kymera

thank you a | Kymera

See More

Kymera

Investor Day Presentation Decks

Biotechnology Decks

Healthcare Decks

Explore Topics

Tumor

Inhibitor

Solid tumor

Drug development

Drug discovery

Recent decks by Kymera

Investor Presentation

December 2023

Investor Presentation

November 2023

Investor Presentation

August 2023

Investor Presentation

June 2023

See all presentations by Kymera (7 decks)

Related decks

Relay Therapeutics

IPO

July 2020

Nuvalent

Investor Presentation

May 2023

Nuvalent

Investor Presentation

November 2023

Nuvalent

Investor Presentation

October 2023

Erasca

Investor Presentation

August 2023

Nuvectis Pharma

Investor Presentation

August 2023

Erasca

Investor Presentation

November 2023

Nuvectis Pharma

Investor Presentation

January 2024

Recent decks by Kymera

See all presentations (7 decks)

Investor Presentation

December 2023

Investor Presentation

November 2023

Investor Presentation

August 2023

Investor Presentation

June 2023

Related decks

Relay Therapeutics

IPO

July 2020

Nuvalent

Investor Presentation

May 2023

Nuvalent

Investor Presentation

November 2023

Nuvalent

Investor Presentation

October 2023

Erasca

Investor Presentation

August 2023

Nuvectis Pharma

Investor Presentation

August 2023

Erasca

Investor Presentation

November 2023

Nuvectis Pharma

Investor Presentation

January 2024

Search Thousands of Presentations by World Leading Companies

Trending:

Addressable Market

Management Team

Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Investment Banking

Explore

Presentation Collections

Slide Collections

Company

© 2021-2024 Slidebook.io